

HEALEY ALS Platform Trial

Weekly Q&A – Aug 25, 2022



Healey Center

Sean M. Healey & AMG Center
for ALS at Mass General



The AMG Foundation

Guest Speaker

Hani A. Kushlaf, MD, FAAN, FANA, FAANEM
Platform Trial Site Investigator
University of Cincinnati, OH





IN SCIENCE LIVES HOPE.

- University of Cincinnati
- GARDNER
NEUROSCIENCE
INSTITUTE

Hani Kushlaf, MD, FAAN

**UC Health ALS Center and
Research**

8/25/2022



UC Health ALS Center



UC Gardner Neuroscience Institute



UC Health Daniel Drake Center

ALS Center Team

- Clinicians: Robert Neel, Jacqueline Janecek
 - Physical therapist: Abbie Homan
 - Occupational therapist: Connie Budda
 - Speech therapist: Courtney Anness
 - Social worker: Yvonne Dressman
 - Nurse Coordinator: Kaitlin Dixon
 - Respiratory therapist: Ann Compton
-
- We follow, on average, 170-180 ALS patients



Our research team:


- Site investigator: Hani Kushlaf
- Subinvestigator: Jacki Janecek
- Senior research coordinator: Ashley Smith
- Research coordinator: Elizabeth Gehlmann

- Healey ALS Platform Trials, Regimen E
 - 8 patients in screening/screened for master protocol
 - 4 patients enrolled in regimen E

- Two retrospective studies:
 - The Prevalence of genetic variants causing ALS in our UC ALS cohort
 - The Correlation of pulmonary function with prognosis in our UC ALS cohort



The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Enrollment Updates (as of Aug 25, 2022)

- **122** individuals have signed informed consent
- **81** individuals have been randomized within Regimen E


Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

47 Sites Currently Activated for Regimen E



(as of 8/25/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

- Lehigh Valley Health Network
- Mass General Hospital
- University of Kansas
- University of Maryland
- California Pacific Medical Center
- Northwestern University
- Virginia Commonwealth University
- University of Nebraska
- Washington University
- Wake Forest University
- Hospital for Special Care
- Saint Alphonsus Regional
- University of Massachusetts
- Duke University
- Barrow Neurological Institute
- Georgetown University
- Texas Neurology
- Beth Israel Deaconess Medical Center
- SUNY Upstate
- Spectrum Health
- Henry Ford Hospital
- Essentia Health
- University of Southern California
- University of South Florida
- University of Colorado
- Providence Brain and Spine
- University of Minnesota
- Loma Linda University
- University of Iowa
- Swedish Medical Center
- Ohio State University
- University of Cincinnati
- Thomas Jefferson University
- UC San Francisco
- Mayo Rochester
- University of Washington
- Vanderbilt University
- UPMC
- Indiana University
- Augusta University
- University of Utah
- Holy Cross Hospital
- Penn State Hershey
- University of CA, Irvine
- Cedars Sinai Medical Center
- University of Pennsylvania
- Nova Southeastern University

Site Map & Contacts:



<https://bit.ly/3g2NZr5>

Patient Navigation

Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar
registration:



<https://bit.ly/3r6Nd2L>

ALS Link sign-up:



<https://bit.ly/3o2Ds3m>



Allison Bulat

Upcoming Guest Speakers:

September 1st- Hosted by James Berry, MD, MPH

September 15th- Tawfiq Al-Lahham, MD (Site Investigator at UPMC in PA)

September 22nd- Mariah Connolly and Meghan Hall (Site Monitors for the Platform Trial)